Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › UGN-102

UGN-102

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of UGN-102

2 trials tracked of UGN-102: 1 in phase 3 or 4.

2Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1
  1. Phase 3 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) Completed
  2. Phase 2 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
UGN-102 yields 80% complete response at 3 months in recurrent LG-IR-NMIBC
Drug Pipeline Phase III
UGN-102 yields 80% complete response at 3 months in recurrent LG-IR-NMIBC New treatment shows promise for recurrent low-grade bladder cancer
This single-arm phase 3 trial evaluated 6 weekly intravesical instillations of UGN-102 in 240 patients with recurrent low-grade intermediate…
A new treatment called UGN-102 helped 80% of patients with recurrent bladder cancer achieve a complete response within three months.
Sep 20, 2026